ADMA Biologics (NASDAQ:ADMA) Price Target Raised to $25.00 at Raymond James

ADMA Biologics (NASDAQ:ADMA) had its target price lifted by Raymond James from $18.00 to $25.00 in a research note released on Friday,Benzinga reports. They currently have a strong-buy rating on the biotechnology company’s stock.

A number of other analysts have also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of ADMA Biologics in a report on Monday, October 14th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, ADMA Biologics currently has an average rating of “Buy” and an average price target of $21.25.

ADMA Biologics Stock Up 14.7 %

Shares of ADMA traded up $2.90 during mid-day trading on Friday, reaching $22.62. 9,717,443 shares of the stock traded hands, compared to its average volume of 3,667,173. The firm has a market cap of $5.27 billion, a price-to-earnings ratio of 80.79 and a beta of 0.64. The stock has a fifty day simple moving average of $18.12 and a 200 day simple moving average of $13.84. ADMA Biologics has a 12-month low of $3.60 and a 12-month high of $23.52. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business’s revenue was up 78.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.02) earnings per share. Sell-side analysts expect that ADMA Biologics will post 0.49 EPS for the current fiscal year.

Insider Transactions at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 466,900 shares of company stock worth $8,224,121. Insiders own 3.70% of the company’s stock.

Institutional Trading of ADMA Biologics

A number of hedge funds have recently bought and sold shares of the company. USA Financial Formulas lifted its stake in ADMA Biologics by 8.6% during the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 539 shares in the last quarter. Vontobel Holding Ltd. lifted its position in shares of ADMA Biologics by 7.0% in the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock worth $273,000 after purchasing an additional 888 shares in the last quarter. Hollencrest Capital Management purchased a new stake in shares of ADMA Biologics in the third quarter worth approximately $30,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of ADMA Biologics by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 1,509 shares in the last quarter. Finally, Chartwell Investment Partners LLC lifted its position in shares of ADMA Biologics by 0.8% in the third quarter. Chartwell Investment Partners LLC now owns 249,779 shares of the biotechnology company’s stock worth $4,993,000 after purchasing an additional 2,038 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.